Cardiovascular disease begins at the cellular level — with oxidative stress, endothelial dysfunction, and vascular inflammation that standard labs often miss until significant damage has occurred. SynergyO3 addresses these root drivers through EBOO ozone therapy, targeted IV therapy, and cardiovascular-specific regenerative protocols.
Recognition is the first step. Dr. Volpp evaluates your complete clinical picture at your physician-led consultation.
Every patient begins with a consultation with Dr. Heather Volpp, MD. Your full clinical picture is reviewed before any protocol is designed.
SynergyO3 identifies upstream biological drivers — oxidative stress, toxin burden, immune dysregulation, pathogen load — rather than treating symptoms in isolation.
EBOO, HOCATT®, IV therapy, and regenerative biologics work as a system — addressing multiple physiological drivers simultaneously for compounding outcomes.
Cardiovascular disease is fundamentally a disease of oxidative stress, inflammation, and endothelial dysfunction — not simply elevated cholesterol. The endothelium (the single-cell lining of every blood vessel) is the first target of oxidative and inflammatory damage, and its dysfunction initiates the arterial stiffness, plaque formation, and microvascular impairment that progress to cardiac events.
Key upstream drivers include elevated homocysteine, oxidized LDL, chronic inflammation (high-sensitivity CRP), poor red blood cell flexibility, and impaired nitric oxide production — many of which go undetected on standard lipid panels and basic metabolic labs.
SynergyO3 evaluates advanced cardiovascular biomarkers alongside conventional testing, and addresses vascular health through EBOO's documented improvements in red blood cell oxygen delivery, endothelial function, and cardiovascular oxidative stress reduction.
Advanced cardiovascular risk markers — oxidized LDL, Lp(a), homocysteine, hsCRP, TMAO — tell a more complete story than total cholesterol alone. SynergyO3 evaluates and addresses the oxidative and inflammatory cardiovascular risk factors that statins and blood pressure medications do not target.
Book Consultation →Statins reduce LDL effectively but do not address oxidized LDL, elevated homocysteine, endothelial inflammation, or the oxidative stress driving vascular damage. Cardiovascular events occur in patients with normal LDL.
Standard cardiovascular care focuses on large vessel disease. Microvascular dysfunction — the impaired blood flow to small vessels supplying the heart, brain, kidneys, and peripheral tissues — is frequently overlooked and independently dangerous.
Diet and exercise recommendations, while valid, do not address the underlying oxidative damage and endothelial dysfunction already present. Without targeted interventions, the cellular environment driving cardiovascular disease continues.
Extra-corporeal Blood Ozone and Oxygenation (EBOO) is a closed-circuit medical procedure that ozonates your blood outside the body — driving systemic physiological changes targeted at the specific mechanisms driving your condition.
EBOO improves erythrocyte deformability — allowing red blood cells to flex and pass through capillaries more efficiently, dramatically improving oxygen delivery to cardiac and peripheral tissue.
Ozone therapy upregulates nitric oxide synthase and protects the endothelium from oxidative damage — supporting the vasodilatory function and anti-thrombotic properties of healthy vascular walls.
EBOO activates Nrf2 antioxidant pathways, reducing the oxidized LDL, vascular inflammation, and oxidative stress that drive atherosclerosis and cardiovascular events.
Enhanced red blood cell oxygen delivery and improved microcirculation directly benefit cardiac muscle oxygenation — supporting function in patients with reduced coronary perfusion.
HOCATT® provides cardiovascular benefit through its carbonic acid component — a potent vasodilator that mimics the cardiovascular effects of moderate aerobic exercise, improving vascular tone and peripheral circulation without physical exertion. This makes HOCATT® particularly valuable for cardiac patients who cannot exercise intensively, or as a complement to an exercise program in healthier patients seeking cardiovascular optimization.
Ask About HOCATT® →Ozone absorbed through skin delivers anti-inflammatory effects without the intensity of systemic EBOO.
Deep tissue heating supports detoxification, reduces musculoskeletal pain, and stimulates mitochondrial activity.
CO2 dissolved in steam causes potent vasodilation — improving peripheral circulation and oxygen delivery.
Completely non-invasive. Patients sit reclined inside the HOCATT® pod. No needles, no downtime.
EBOO has been used in cardiovascular medicine in Europe and integrative practice for decades. Patients with recent cardiac events, devices, or active anticoagulation are evaluated carefully before any protocol begins.
Ozone therapy's improvements in endothelial function and nitric oxide pathways can support healthy blood pressure regulation. It is not a replacement for antihypertensive medications — it addresses the vascular biology underlying hypertension.
Homocysteine is an amino acid that at elevated levels directly damages the vascular endothelium and significantly increases cardiovascular risk — independent of LDL. It responds well to methylated B vitamins.
Post-cardiac recovery support is an appropriate use case. Timing depends on the nature of the cardiac event and current medications. Dr. Volpp coordinates with your cardiologist.
Yes — particularly through the carbonic acid vasodilation effect, which improves vascular tone and peripheral circulation. HOCATT® is not appropriate for patients with severe, unstable cardiac disease without physician clearance.
EDTA chelation therapy addresses heavy metal burden and may improve cardiovascular risk through different mechanisms. SynergyO3 evaluates heavy metal burden as part of the cardiovascular assessment — if significant, chelation may be incorporated.
After an initial series, monthly or quarterly EBOO maintenance sessions are typical. The cadence is individualized based on biomarker response and clinical status.
Insurance is not accepted. Superbills for HSA/FSA reimbursement are available. Written pricing is always provided before services.
Before any treatment begins, Dr. Volpp reviews your complete health history, labs, and goals. Every protocol is physician-designed for your specific biology — not a template.
Book Your Consultation →(760) 450-4602 · info@synergyo3.com · Mon-Fri 9:00am-5:00pm
Insurance not accepted · HSA/FSA superbills available · Written quotes before all services